Physician profile
Niraj S Shah
NPI 1134119597
$3,975.77
in general payments reported to CMS, 2019-2025
28 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $215 · 2021: $862 · 2022: $835 · 2023: $584 · 2024: $678 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $19.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.85 |
| Education | $19.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $991.06 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $747.83 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $219.83 | 2020-2024 | |
| Abbvie INC. | $208.49 | 2023-2025 | Vraylar |
| Amgen INC. | $206.84 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.67 | 2020-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Terumo Medical Corporation | $143.30 | 2025 | Navicross, Glidewire |
| Glaxosmithkline, LLC. | $137.24 | 2021-2025 | Nucala |
| Vanda Pharmaceuticals INC. | $132.42 | 2021-2022 | |
| Abbott Laboratories | $118.41 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $115.42 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $114.13 | 2021-2023 | |
| Dexcom, INC. | $112.09 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $65.80 | 2024-2025 | Zenpep |
| Ultragenyx Pharmaceutical INC. | $63.07 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.91 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $50.13 | 2019 | |
| Merck Sharp & Dohme LLC | $49.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $41.56 | 2021 | |
| Genentech USA, INC. | $36.90 | 2019-2020 | |
| Astellas Pharma US INC | $29.66 | 2025 | Izervay |
| Takeda Pharmaceuticals U.S.A., INC. | $24.97 | 2024 | Eohilia |
| Horizon Therapeutics Plc | $20.21 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $19.12 | 2023 | Rayaldee |
| Biohaven Pharmaceutical Holding Company LTD. | $18.41 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.40 | 2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $15.71 | 2021 | |
| Esperion Therapeutics, INC. | $13.68 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.